Eli Lilly and Company (NYSE:LLY) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Eli Lilly and Company (NYSE:LLY) from a buy rating to a strong-buy rating in a research note released on Sunday morning.

Other analysts have also issued research reports about the company. Rothschild & Co Redburn lifted their price objective on Eli Lilly and Company from $775.00 to $830.00 and gave the stock a “neutral” rating in a report on Monday, January 26th. Loop Capital set a $1,200.00 target price on Eli Lilly and Company in a report on Tuesday, February 10th. Truist Financial reissued a “buy” rating on shares of Eli Lilly and Company in a research report on Monday, February 23rd. CICC Research boosted their price target on Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a “neutral” rating in a research note on Wednesday, February 11th. Finally, Scotiabank reaffirmed an “outperform” rating and set a $1,300.00 price target on shares of Eli Lilly and Company in a research report on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $1,221.26.

Eli Lilly and Company Stock Up 3.6%

Shares of Eli Lilly and Company stock opened at $918.12 on Friday. The company has a market cap of $867.46 billion, a price-to-earnings ratio of 40.01, a price-to-earnings-growth ratio of 1.03 and a beta of 0.40. The company’s 50 day moving average is $1,001.75 and its 200 day moving average is $966.95. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,133.95. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. The business had revenue of $19.29 billion during the quarter, compared to the consensus estimate of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The firm’s revenue was up 42.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Institutional Investors Weigh In On Eli Lilly and Company

A number of institutional investors have recently bought and sold shares of the business. Exencial Wealth Advisors LLC grew its position in Eli Lilly and Company by 189.6% in the third quarter. Exencial Wealth Advisors LLC now owns 17,408 shares of the company’s stock worth $13,283,000 after acquiring an additional 11,396 shares in the last quarter. Rede Wealth LLC purchased a new stake in Eli Lilly and Company during the third quarter valued at approximately $487,000. Central Pacific Bank Trust Division lifted its stake in shares of Eli Lilly and Company by 25.8% in the 3rd quarter. Central Pacific Bank Trust Division now owns 8,990 shares of the company’s stock valued at $6,859,000 after purchasing an additional 1,843 shares during the last quarter. Cidel Asset Management Inc. boosted its holdings in shares of Eli Lilly and Company by 26.5% in the 3rd quarter. Cidel Asset Management Inc. now owns 26,726 shares of the company’s stock worth $20,392,000 after purchasing an additional 5,591 shares during the period. Finally, Coldstream Capital Management Inc. boosted its holdings in shares of Eli Lilly and Company by 25.6% in the 3rd quarter. Coldstream Capital Management Inc. now owns 42,418 shares of the company’s stock worth $32,365,000 after purchasing an additional 8,659 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly agreed to buy Centessa Pharmaceuticals in a cash deal that pays $38/share upfront with contingent value rights that can lift the total to roughly $7.8 billion; the acquisition brings Centessa’s OX2R agonist sleep‑wake program (lead asset cleminorexton) into Lilly’s neuroscience pipeline and reduces reliance on a single franchise for future growth. Lilly to acquire Centessa press release
• Positive Sentiment: Lilly expanded its AI drug‑discovery partnership (Insilico/Insilico Medicine) in a deal worth up to ~$2.75 billion, aiming to speed molecule discovery and lower R&D costs — a strategic move that could increase pipeline throughput and long‑term earnings visibility. Lilly extends Insilico partnership (Reuters)
• Neutral Sentiment: Market reaction to the Centessa deal sent Centessa (CNTA) shares sharply higher and drove options activity; that reflects dealcertainty and investor demand for sleep‑med assets but is more about the target than an immediate P&L boost for Lilly. Options Traders Pick Up Pharma Stock After Eli Lilly Buyout
• Neutral Sentiment: Analyst/market notes were mixed: some firms keep buy ratings (Guggenheim maintained buy while trimming its target slightly) — a sign analysts view the strategic moves as supportive but remain cautious on valuation. Guggenheim price-target note (Benzinga)
• Negative Sentiment: Competitive risk: Novo Nordisk launched a multi‑month subscription for Wegovy (cash‑pay patients) to undercut prices and win share in the obesity/GLP‑1 market — increased pricing competition could pressure Lilly’s high‑margin GLP‑1 cash sales over time. Novo launches Wegovy subscription (CNBC)

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.